{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"2.86","upperLimit":"NA","value":"3.72"},{"groupId":"OG001","lowerLimit":"3.52","upperLimit":"10.26","value":"4.57"},{"comment":"Median, lower and upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median, lower and upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median, and upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG004","lowerLimit":"3.19","upperLimit":"NA","value":"NA"},{"comment":"Median, and upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG005","lowerLimit":"9.11","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"3.52","upperLimit":"7.47","value":"5.86"},{"comment":"Upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG007","lowerLimit":"4.84","upperLimit":"NA","value":"10.89"},{"groupId":"OG008","lowerLimit":"3.49","upperLimit":"5.59","value":"3.72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"17"},{"groupId":"OG008","value":"8"}],"units":"Participants"}],"description":"Duration of disease control is the time from the first dose to the first objective response of PD, or death, whichever occurs first, for participants who reported a best overall response of SD or better. PD was defined as at least a 20% increase in the SOD of target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the Baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Colorectal Cancer received epacadostat 100 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG000","title":"Phase 2: Epacadostat 100 mg + Nivolumab 240 in Colorectal Cancer"},{"description":"Participants with DLBCL received epacadostat 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG001","title":"Phase 2: Epacadostat 300 mg + Nivolumab 240 mg in DLBCL"},{"description":"Participants with Melanoma(I/O Naive) received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG002","title":"Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg in Melanoma(I/O Naive)"},{"description":"Participants with Melanoma (I/O Relapsed) received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG003","title":"Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Relapsed)"},{"description":"Participants with Melanoma (I/O Refractory) received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG004","title":"Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Refractory)"},{"description":"Participants with NSCLC received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG005","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in NSCLC"},{"description":"Participants with Ovarian Cancer received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG006","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Ovarian Cancer"},{"description":"Participants with SCCHN received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG007","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in SCCHN"},{"description":"Participants with Glioblastoma received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG008","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Glioblastoma"}],"paramType":"MEDIAN","populationDescription":"The Phase 2 Full Analysis Population includes all participants enrolled in the study who received at least 1 dose of study drug. The data is reported per cancer type in this outcome measure. Overall number analyzed are the participants who had best overall response of stable disease or better.","reportingStatus":"POSTED","timeFrame":"From first dose up end of the study (up to approximately 6 years)","title":"Phase 2: Duration of Disease Control, Defined as CR, PR, and Stable Disease (SD)","type":"SECONDARY","unitOfMeasure":"months"}